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Donor killer cell immunoglobulin-like receptor (KIR)-ligand
incompatibility is associated with decreased relapse incidence
(RI) and improved leukemia-free survival (LFS) after haploiden-
tical and HLA-mismatched unrelated hematopoietic stem cell
transplantation. We assessed outcomes of 218 patients with
acute myeloid leukemia (AML n¼ 94) or acute lymphoblastic
leukemia (n¼124) in complete remission (CR) who had
received a single-unit unrelated cord blood transplant (UCBT)
from a KIR-ligand-compatible or -incompatible donor. Grafts
were HLA-A, -B or -DRB1 matched (n¼21) or mismatched
(n¼ 197). Patients and donors were categorized according to
their degree of KIR-ligand compatibility in the graft-versus-host
direction by determining whether or not they expressed
HLA-C group 1 or 2, HLA-Bw4 or HLA-A3/-A11. Both HLA-C/-B
KIR-ligand- and HLA-A-A3/-A11 KIR-ligand-incompatible
UCBT showed a trend to improved LFS (P¼ 0.09 and P¼ 0.13,
respectively). Sixty-nine donor–patient pairs were HLA-A, -B or
-C KIR-ligand incompatible and 149 compatible. KIR-ligand-
incompatible UCBT showed improved LFS (hazards ratio¼ 2.05,
P¼0.0016) and overall survival (OS) (hazards ratio¼ 2.0,
P¼0.004) and decreased RI (hazards ratio¼0.53, P¼ 0.05).
These results were more evident for AML transplant recipients
(2-year LFS and RI with or without KIR-ligand incompatibility 73
versus 38% (P¼ 0.012), and 5 versus 36% (P¼0.005), respec-
tively). UCBT for acute leukemia in CR from KIR-ligand-
incompatible donors is associated with decreased RI and
improved LFS and OS.
Leukemia (2009) 23, 492–500; doi:10.1038/leu.2008.365;
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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) from
family, unrelated bone marrow or cord blood donors is a
curative treatment for a considerable number of patients with
acute leukemia. Major histocompatibility complex-restricted
donor T cells play an important role in HLA-matched as well as
HLA-mismatched HSCT by recognizing differences in minor and
major histocompatibility antigens between donor and recipi-
ent.1,2 A novel mechanism that relies on interactions between
donor natural killer (NK) cells and recipient cells was demon-
strated in the setting of haploidentical family donor HSCT.3–5
NK cells express on their surface inhibitory killer cell
immunoglobulin-like receptors (KIRs) that recognize allotypic
determinants (‘KIR ligands’) shared by certain HLA class I allele
groups. KIR2DL1 recognizes HLA-C alleles with a Lys80 residue
(HLA-Cw4 and related, ‘group 2’ alleles), KIR2DL2 and
KIR2DL3 recognize HLA-C with an Asn80 residue (HLA-Cw3
and related, ‘group 1’ alleles); KIR3DL1 is the receptor for HLA-
B alleles sharing the Bw4 supertypic specificity.3–5 Finally,
KIR3DL2 was shown to function as a receptor for HLA-A3/-A11
alleles when bound to Epstein–Barr virus (EBV) peptides.6
The role of KIR and KIR ligand in the context of HSCT has
been investigated over the past 10 years. In transplants that are
KIR-ligand mismatched in the graft-versus-host (GvH) direction,
donor NK cells expressing inhibitory KIRs, which do not
recognize ligand(s) on recipient targets, are released from HLA
inhibition and mediate alloreactions leading to clinically
significant graft-versus-leukemia effects. Clinical studies in
haploidentical7–9 and in some (un)related donor transplants10–12
showed that KIR-ligand incompatibilities in the GvH direction
are associated with a decreased incidence of relapse and
improved disease-free and overall survival (OS) after HSCT.
Several unrelated donor transplant studies did not, however,
report any effect.13–17
Umbilical cord blood units from unrelated donors constitute
another well-established source of stem cells for HSCT in
patients with leukemias. The main advantages are rapid
availability and the possibility to perform HLA-mismatched
transplantations due to a relatively low risk of severe GvH
disease (GvHD)18–21 that increases considerably the probability
of finding a suitable donor. Moreover, outcomes after umbilical
cord blood transplants (UCBTs) are comparable with those after
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unrelated bone marrow transplantation in children and adults
with acute leukemias.19,21
We hypothesized that in the setting of HLA-mismatched
UCBT, NK-cell alloreactivity might come into play and
influence outcomes. From the Eurocord database we retrieved
all patients who had received a single-unit UCBT for acute
leukemia in complete remission (CR). We grouped transplants
according to the presence or absence of KIR-ligand mismatches
that were shown to trigger donor-versus-recipient NK-cell
alloreactivity in haploidentical transplantation, that is mis-
matches for HLA-C group 1, HLA-C group 2 and the HLA-
Bw4 allele group. Moreover, as HLA-A3/-A11 KIR-ligand
mismatches were not encountered in haploidentical transplants,
we decided to include them in our evaluation. As HLA-A3/-A11
alleles were reported to function as KIR ligands when bound to
EBV peptides, we hypothesized that, in view of the frequent EBV
reactivation after transplantation, EBV peptides were readily
available for HLA-A3/-A11 binding, with the possible generation
of HLA-A3/-A11-specific donor NK cells that were alloreactive




This retrospective analysis is based on data reported to the
Eurocord Registry from European and non-European centers
through a standardized questionnaire concerning patient, cord
blood units, disease and graft characteristics, as well as
transplant outcomes. The collected information was reviewed
by two physicians and checked for computer-generated errors to
ensure data quality.
All patients or their legal guardians gave informed consent for
UCBT according to the Declaration of Helsinki. This study was
approved by the Eurocord institutional review board.
Criteria for patient selection
The following criteria were required: (1) acute leukemia in CR,
(2) HLA high-resolution typing for HLA-A, HLA-B, HLA-C and -
DRB1 of patients and cord blood units, or HLA-A high-
resolution typing for those cord blood units without complete
high-resolution typing for HLA-B and/or HLA-C, (3) non-
expanded, single, unrelated cord blood unit and (4) complete
clinical data during at least 3 months of follow-up.
Inhibitory KIR-ligand assessment in recipients and
donors
As of 1 October 2007, 218 patient–donor pairs met the
eligibility criteria. Complete information on high-resolution
typing for HLA-A, HLA-B, HLA-C and HLA-DRB1 was available
for 218 patients and 198 donors, and sufficient information on
high-resolution typing for HLA-A and either HLA-B or HLA-C
was available for 20 donors to determine KIR-ligand (in)compat-
ibility in the GvH direction.
High-resolution typing of recipient and donor HLA-B and
HLA-C alleles was used to segregate patients and cord blood
units in the following KIR-ligand groups as described earlier by
Ruggeri et al.22 HLA-C group 1 alleles; HLA-C group 2 alleles;
and HLA-Bw4 group alleles. Non-HLA-Bw4 alleles were
grouped in the HLA-Bw6 allele group, which is not a KIR
ligand. In addition, patients and cord blood units were grouped
according to whether or not they displayed HLA-A3/-A11
alleles, which are putative KIR ligands.6
Composition of the study group for KIR-ligand
(in)compatibility in the GvH direction
HLA-C group 1 or 2 alleles, which were present in the cord
blood units, were missing in 41 transplant recipients; HLA-Bw4
group alleles were missing in 12 and HLA-A3/-A11 in 22
patients. Combination of the data on HLA-A, HLA-B and HLA-C
of donors and recipients resulted in 69 (32%) donor–patient
pairs with KIR-ligand incompatibility in the GvH direction. Fifty-
one patients were HLA-C, group 1 or 2, 19 patients HLA-Bw4
and 18 patients HLA-A3/-A11 KIR-ligand mismatched in the
host-versus-graft direction with the donor. Pairs in which the
donor did not miss a ligand in the patient but did not possess a
KIR ligand present in the recipient (n¼ 50) were pooled with the
99 KIR-ligand-matched pairs and, for the purpose of data
analyses, are henceforth referred to as the KIR-ligand-compa-
tible or -matched group, which comprised a total of 149 (68%).
End points
The main end points were leukemia-free survival (LFS), which
was defined as the time from transplantation to either first
relapse or death in CR; relapse incidence (RI), defined as any
morphologically proven recurrence of leukemia occurring after
the allograft; and OS, defined as the time from transplantation
until the date of death. Patients were censored at the time of
relapse or of the last follow-up.
Other end points were engraftment, non-relapse mortality
(NRM) and acute or chronic GvHD. For engraftment, we
considered the incidence of neutrophil recovery as defined by a
neutrophil count of at least 0.5 109/l for three consecutive
days and graft failure as no sign of neutrophil recovery as well as
transient engraftment of donor cells within 60 days after
transplantation. Chimerism data were available during the first
3 months after UCBT. Full donor chimerism was defined as the
presence of more than 95% of the donor cells, mixed chimerism
if more than 5% and less than 95% were donor cells and
autologous recovery if less than 5% of cells were donor cells.
Data on the methodology of chimerism detection were not
available. Acute GvHD at day 100 was diagnosed and graded
according to published criteria,23 with histopathological
confirmation when possible. NRM at 2 years was defined as
deaths related to transplantation and not to relapse, and chronic
GvHD at 2 years was diagnosed according to standard
criteria23,24 and evaluated in patients who survived at least
100 days with sustained engraftment.
Statistical analysis
Data were analyzed from the Eurocord database with the
existing data as of October 2007. The duration of follow-up was
the time to the last assessment for survivors. Variables related to
the patient, to the disease, to the cord blood donor and to
the transplant were compared (according to KIR-ligand
compatibility status) using the w2 test for categorical and the
Mann–Whitney test for continuous variables. All P-values are
two-sided with type-1 error rate fixed at 0.05.
To analyze the outcome, we considered variables associ-
ated with the recipient (age, weight at time of transplantation,
sex and cytomegalovirus (CMV) status), with the disease (acute
myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL), first, second or subsequent CR, and separately for ALL and
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AML: good-, standard- or bad-risk cytogenetics), with the cord
blood donor (HLA disparity, infused total nucleated cell and
CD34þ cell doses) and with the transplant (year of transplant,
reduced-intensity or myeloablative conditioning regimen, use of
total body irradiation, use of ATG and GvHD prophylaxis).
Cumulative incidence curves were used for RI and NRM in a
competing risk setting, as death and relapse are competing
together. Relapse and death in remission were considered as
competing events to study neutrophil recovery, and acute and
chronic GvHD.25,26 Gray test was used for univariate compar-
isons.27 Probabilities of LFS and OS were calculated using the
Kaplan–Meier estimate; the two-sided log-rank test was used for
univariate comparisons.
Factors associated with a P-value less than 0.10 by univariate
analysis were included in multivariate analyses, using Cox
proportional hazards for LFS and OS, and proportional
subdistribution hazard regression model of Fine and Gray28 for
acute and chronic GvHD, neutrophil recovery, RI and NRM.
Then a stepwise regression was performed using a threshold of
0.05. The diagnosis (AML and ALL) was added to the final
model. All tests are two sided. The type I error rate was fixed at
0.05 for the determination of factors associated with time-to-
event outcomes. Statistical analyses were performed with SPSS
(SPSS Inc., Chicago, IL, USA) and S-Plus (MathSoft Inc., Seattle,
WA, USA) software packages.
As the effects of KIR(-ligand) mismatching have been
described to be associated with AML, a limited subgroup
analysis was performed with respect to KIR-ligand incompat-
ibility for patients with AML or ALL, separately.
Results
Patients, donor and transplant characteristics, and
overall results of UCBT of the study group
The study group comprised 218 patients, undergoing a single-
unit UCBT for AML or ALL in CR between 1997 and 2007
(median 2004). The median follow-up time is 14 months. The
transplantations were performed in 57 centers. The cord blood
units were supplied by 29 cord blood donor banks, mostly
belonging to Netcord organization. Table 1 summarizes patient,
donor and transplant characteristics for the patients transplanted
with donors that were KIR-ligand incompatible (n¼ 69) or KIR-
ligand compatible (n¼ 149) in the GvH direction. The diagnoses
included ALL and AML, with good-, standard- or bad-risk
cytogenetics in the first, second or third CR. The stages of both
diseases were divided equally between the two groups.
However, among patients with known cytogenetics, 17 AML
patients out of 18 with a KIR-ligand-incompatible donor and 33
AML patients out of 57 with a KIR-ligand-compatible donor had
bad-risk cytogenetics (P¼ 0.02). CMV status was reported in
204 patients (111 positive) and in 202 cord blood donors (11
CMV positive). Combined information is available in 187
patient–donor pairs, of which 86 were both negative and 93
were patient positive/donor negative. EBV status of patients was
reported in only 74 cases (34% of all patients) of which 58 were
positive (78%) and in 78 donors (36% of all donors). CMV and
EBV status were equally divided between the two KIR-ligand
groups. The number of HLA disparities between donors and
recipients was not significantly different between the two
groups. Although a number of myeloablative and reduced-
intensity conditioning regimens with or without ATG were used
in the 57 participating transplant centers, the frequencies of
myeloablative and reduced-intensity regimens and of use of
ATG were not statistically different between the two KIR-ligand
groups as well as other patient-, disease-, donor- and transplant-
related factors (Table 1). Overall outcomes of the entire study
group with respect to neutrophil engraftment, acute and chronic
GvHD, non-relapse mortality, RI, LFS and OS are shown in
Table 2.
Association of KIR-ligand incompatibility in the GvH
direction with LFS, OS and RI
LFS and OS. To assess the impact of KIR-ligand mismatches
that were shown to trigger donor-versus-recipient NK-cell
alloreactivity in haploidentical transplantation, we determined
LFS at 2 years for the donor–patient combinations that were
mismatched (in the GvH direction) for HLA-C and/or HLA-Bw4
KIR ligands. It was 48±9 versus 36±4% (P¼ 0.09) for those
who were KIR-ligand matched.
As we had a relatively large group of 22 donor–recipient pairs
that were mismatched for HLA-A3/-A11 (in the GvH direction),
we were able to assess for the first time the role of this putative
KIR ligand in transplantation outcomes; LFS was 62±11% for
the donor–patient combinations that were mismatched for HLA-
A3/-A11 versus 35±4% for those who were not A3/A11
mismatched (P¼ 0.13). As both analyses demonstrated an
increased LFS in an almost not overlapping fashion and as only
six patients had two incompatibilities consisting of HLA-C group
and/or HLA-Bw4 group incompatibilities in combination with
an HLA-A3 and/or -A11 mismatch, we combined the two groups
and performed a common statistical analysis.
Leukemia-free survival was significantly improved in patients
receiving a UCBT from an HLA-A, -B or -C KIR-ligand
incompatible donor compared with those who were trans-
planted with an HLA-A, -B or -C KIR-ligand compatible donor
(in the GvH direction). The estimates for LFS at 2 years are
55±7 and 31±4% (P¼ 0.005), respectively, for patients with
and without donor KIR-ligand incompatibility in the GvH
direction (Figure 1a).
Overall survival was also improved in patients receiving a
UCBT from a KIR-ligand-incompatible donor compared with
those who were transplanted with a KIR-ligand-compatible
donor. The estimates for 2-year OS were 57±7 and 40±4%
(P¼ 0.02), respectively, for patients with and without donor KIR-
ligand incompatibility in the GvH direction (Figure 1b).
In univariate analysis, which included age, sex, CMV status,
diagnosis (AML or ALL), stage of the disease, infused total
number of cells or of CD34þ cells, HLA disparities, condition-
ing regimen, use of total body irradiation or ATG and KIR-ligand
incompatibility (in the GvH direction), only o2 HLA disparity
was associated with OS (P¼ 0.008).
In multivariate analysis, KIR-ligand incompatibility was an
independent risk factor associated with improved LFS and OS.
Compatible HLA grafts or with one HLA disparity were also
associated with improved OS (Table 3). The estimates for LFS at
2 years for AML and ALL were not significantly different. Within
AML as well as ALL, LFS at 2 years was not different for the
patients with good-, standard- or poor-risk cytogenetics (data not
shown).
Relapse. The 2-year cumulative incidence of relapse was
32±4% for the entire study group, and it was 37±4% for the
KIR-ligand-compatible group compared with 20±5% for the KIR-
ligand-incompatible group (P¼ 0.03) (Figure 1c). In univariate
analysis, other factors associated with RI were type of conditioning
(P¼ 0.05), use of total body irradiation (P¼ 0.08) and ATG
(P¼ 0.09). In a multivariate analysis, myeloablative conditioning
regimen (MAC) (P¼ 0.007), two or more HLA disparities (P¼ 0.05)
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and KIR-ligand incompatibility (P¼ 0.05) were independently
factors associated with a decreased risk of relapse (Table 3).
Association of KIR-ligand incompatibility in the GvH
direction with engraftment, GvHD and NRM
Neutrophil recovery. Cumulative incidence of neutrophil
recovery at day 60 for the entire group was 80±3%, and it was
81±4% for patients with and 79±3% for those without
KIR-ligand incompatibility, respectively (P¼ 0.21). The
median time to neutrophil recovery was 21 days (4–40) for
KIR-ligand-incompatible transplants and 25 (6–60) days for
KIR-ligand-compatible transplants. In univariate analysis, the
incidence of neutrophil recovery was associated with the
median number of nucleated cells infused (P¼ 0.015) and
HLA disparity (P¼ 0.05), but not with KIR-ligand incompat-
ibility. In a multivariate analysis (Table 2), only a higher number
of nucleated cells (43.09 107/kg) infused were associated
with higher rates of neutrophil recovery (P¼ 0.015).
At 3 months after UCBT, chimerism data were available in
158 patients: 126 patients were full donors (80%), 15 had mixed
chimerism (9%) and 17 (10%) had autologous reconstitution.
There was no association between KIR-ligand incompatibility
and full donor chimerism (P¼ 0.40).
Table 1 Patient demographics according to the presence of a KIR-ligand-compatible and -incompatible cord blood donor in 218 UCBT for
patients with acute leukemia in CR
Entire population KIR-ligand-compatible donors KIR-ligand-incompatible donors P-value*
Number of patients 218 149 69
Median age (years) 13.8 (0.5–69) 12.8 (0.6–69) 15 (0.5–64) 0.52
Year of transplant 2004 (97–07) 2004 (97–07) 2004 (98–07) 0.68
Median follow-up 14 months 13 months 15 months
Median weight (kg) 49 (6.5–112) 47 (7–112) 50 (6.5–102) 0.52
Male, n (%) 122 (56) 84 (56) 38 (45) 0.86
Diagnosis, n (%) 0.27
AML 94 (43) 68 (46) 26 (38)
ALL 124 (57) 81 (54) 43 (62)
Cytogenetics (n¼174)a
AML good risk 5 5 0
Standard risk 20 19 1
Bad risk (%) 50 (67) 33 (58) 17 (94) 0.02
ALL good risk 11 8 3
Standard risk 39 24 15
Bad risk (%) 49 (49) 30 (48) 19 (51) 0.76
Status at transplant, n (%) 0.52
1st CR 105 (48) 69 (46) 36 (52)
2nd CR 91 (42) 66 (44) 25 (36)
42nd CR 22 (10) 14 (10) 8 (12)
TNC infused (median 107/kg) 3.09 (0.05–34.3) 3.14 (0.05–34.3) 2.86 (0.7–22.3) 0.29
CD34+ infused (median 105/kg) 1.31 (0.08–10.2) 1.37 (0.08–7.1) 1.2 (0.25–10.2) 0.22
Number of HLA disparities, n (%)b 0.27
6/6 match 21 (10) 16 (11) 5 (7)
5/6 match 94 (43) 66 (44) 28 (41)
4/6 match 93 (43) 57 (39) 36 (52)
3/6 match 8 (3) 8 (5) 0
2/6 match 2 (1) 2 (1) 0
Conditioning regimen, n (%)
RIC (n¼ 202) 35 (17) 25 (18) 10 (16) 0.77
TBI 122 (56) 80 (54) 42 (61) 0.35
Use of ATG/ALG (n¼196) 158 (81) 106 (79) 52 (84) 0.43
GvHD prophylaxis, n (%) 0.76
CsA 25 (11) 17 (12) 8 (12)
CsA+prednisone 137 (63) 90 (60) 47 (68)
CsA+MMF 34 (16) 25 (17) 9 (13)
Other 22 (10) 17 (11) 5 (7)
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG/ALG, antithymocyte/antilymphocyte globulin; CR, complete
remission; CsA, cyclosporin; GvHD, graft-versus-host disease; MMF, mycophenolate mofetil; RIC, reduced-intensity conditioning; TBI, total body
irradiation; TNC, total nucleated cells.
*P-value represents the comparison of each characteristic according to the KIR-ligand group.
aCytogenetic data available for 174 patients (AML, n¼ 75; ALL, n¼ 99): numbers and percentages of patients are given; ALL good risk: del(9p),
t(12p)/t(12;21), t(10;14), t(14q11–q13), hyperdiploid; standard risk: normal cytogenetics and all remaining abnormalities; bad-risk cytogenetics:
t(9;22), t(4;11), t(1;19), t(8;14), 7, +8, abn(11q23), hypodiploid/near triploid, complex abnormalities; AML good risk: t(8;21), inv.16 and t(15;17);
standard risk: normal cytogenetics; bad risk: all other chromosomal abnormalities.
bOn the basis of antigen-level HLA-A and HLA-B and allele-level HLA-DRB1 typing.
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Acute and chronic GvHD. Sixty-five patients presented
grade II–IV acute GvHD (grade II, n¼ 36, 18%; grade III, n¼ 14,
7%; grade IV, n¼ 15, 7%). At day 100, cumulative incidence of
grade II–IV acute GvHD for the entire population was 29±3%,
and it was 28±5% for patients with a KIR-ligand-incompatible
donor and 30±3% for patients with a KIR-ligand-compatible
donor (in the GvHD direction), respectively (P¼ 0.82). The
2-year cumulative incidence of chronic GvHD was 19% (n¼ 29
for 171 patients at risk). There was no association of chronic
GvHD with the KIR-ligand groups.
NRM and non-relapse causes of death. The 2-year
cumulative incidence of NRM was 30±3%, and it was
31±4% for patients with a KIR-ligand-compatible donor and
25±5% for those with a KIR-ligand-incompatible donor
(P¼ 0.34). In a multivariate analysis, only RIC and a lower
number of HLA disparities (compatible or one HLA disparity)
were associated with decreased NRM (Table 3). Death due to
opportunistic infections (viral, fungal and parasitic) was more
frequent in the KIR-ligand-compatible donor group than in the
KIR-ligand-incompatible donor group (Table 4). Unfortunately,
more detailed information on the nature of these lethal
infections is not available in the Eurocord database, but they
occurred equally in the groups of CMV-positive and CMV-
negative patients.
Association of KIR-ligand incompatibility in the GvH
direction with outcomes in patients with AML or ALL in CR
A limited subgroup analysis was performed for 94 patients with
AML (47 patients in first CR; 40 patients in second CR and 7
patients in third CR) and 124 patients with ALL (58 patients in
first CR, 51 patients in second CR and 15 patients in third CR).
In AML UCBT recipients, 2-year cumulative incidence of
relapse was associated with the presence or absence of KIR-
ligand incompatibility in the GvH direction (5±4 versus
36±7%, P¼ 0.005). The 2-year estimates for LFS were
73±10 and 38±7% (P¼ 0.012) and for OS were 70±11 and
36±8% (P¼ 0.016), respectively (Figure 2a).
In spite of the trend of a decreased RI and improved LFS and OS
for those with a KIR-ligand-incompatible donor, there was not a
significant statistical association in ALL patients (Figure 2b).
NRM and acute and chronic GvHD were not influenced by the
diagnosis (AML or ALL) or by the KIR-ligand-compatibility status.
Discussion
This study demonstrates that inhibitory KIR-ligand incompat-
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Figure 1 (a) Estimated leukemia-free survival in patients with Kir-ligand-compatible (_______) (n¼149) or -incompatible (- - - - - - -) donors (n¼ 69),
after UCBT for acute leukemia in CR. (b) Estimated overall survival in patients with Kir-ligand-compatible (_______) (n¼149) or -incompatible
(- - - - - - -) donors (n¼ 69), after UCBT for acute leukemia in CR. (c) Cumulative incidence of relapse in patients with Kir-ligand-compatible (______)
(n¼ 149) or -incompatible (- - - - - - - -) donors (n¼ 69), after UCBT for acute leukemia in CR. CR, complete remission; UCBT, unrelated cord blood
transplant.
Table 2 Overall outcomes after UCBT of 218 patients with acute
leukemia in CR
Outcomes No. of events/patients
at risk
Estimation
Neutrophil recoverya at day 60 137/218 80±3%
Acute GvHDa at day 100 65/205 29±3%
Chronic GvHDa at 2 years 29/171 19±3%
Relapse incidencea at 2 years 58/218 32±4%
Non-relapse mortalitya at 2 years 58/218 30±3%
Leukemia-free survivalb at 2 years 116/218 38±4%
Overall survivalb at 2 years 103/218 45±4%
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associated with a decreased RI and an improved LFS and OS for
patients with acute leukemia transplanted in CR with a single-
unit unrelated umbilical cord blood graft. Multivariate analysis
shows that these findings are independent of the number of HLA
disparities between the donor and recipient.
We confirm our and other previous studies showing that a
higher number of HLA disparities (two or more) are associated
with diminished neutrophil recovery, increased NRM rates and
decreased RI.19,20 In contrast, KIR-ligand incompatibility was
not associated with the cumulative incidence of neutrophil
recovery within 60 days and NRM.
A limitation of our study is the short median follow-up (13
months for the KIR-ligand-matched and 15 months for the KIR-
ligand-mismatched donor–patient pairs) due to the fact that
HLA-C allelic typing has just recently been used for both
umbilical cords and patients. However, the aim of our study was
not to assess the actual risk of relapse after UCBT but to compare
the incidence of relapse after UCBT with or without KIR-ligand
mismatches in the GvH direction. We cannot rule out that a
KIR-ligand-mismatched combination delays relapse, which
would become evident after a longer follow-up.
Different effects of KIR/KIR-ligand incompatibilities on the
outcome of allogeneic SCT have been reported. During the last
10 years, the understanding of NK-cell alloreactivity is rapidly
expanding, and thus the methods, utilized through the years, to
determine KIR mismatch, vary largely. Mismatches between
donor KIR ligand and recipient KIR ligand in the GvH direction
(the donor–recipient KIR-ligand model) have been used by the
Perugia group and Hsu et al.,7–9,12,22 between donor KIR and
recipient KIR by Gagne et al.28 and between donor KIR and
recipient KIR ligand by Leung et al.29,30
Criticizing the donor–recipient KIR-ligand model one could
argue that, as some donors might not have possessed the
relevant KIR gene, a minority of donor–recipient pairs might
have been misclassified in this study. In fact, donor-versus-
recipient NK-cell alloreactivity was predicted on the basis of
KIR-ligand mismatching without the direct assessment of the
donor alloreactive NK-clone repertoire or donor KIR genotyp-
ing. However, it is worth noting that KIR genotyping is required
Table 3 Multivariate analysis for overall survival, leukemia-free
















































Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute
myeloid leukemia; HLA, human leukocyte antigen; MAC, myeloablative
conditioning; RIC, reduced-intensity conditioning; TNC, total nucleated
cells infused.
aOn the basis of antigen-level HLA-A and HLA-B and allele-level HLA-
DRB1 typing.
Table 4 Causes of death according to the presence of a KIR-ligand-
compatible and -incompatible cord blood donor in 218 UCBT for










No. of patients 218 149 69
Cause of death, n (%)
Related to
relapse
44 (45) 36 (46) 8 (35)
Related to
transplant
58 (55) 43 (54) 15 (65) 0.36
If transplant related (n)




VOD 2 2 0
Hemorrhage 3 2 1




Viral infection 7 7 0










ARDS 3 3 0









17 (30) 16 (38) 1 (7) 0.03b
Abbreviations: ARDS, acute respiratory distress syndrome; GvHD,
graft-versus-host disease; LPD EBV, EBV-related lymphoproliferative
disease; VOD, veno-occlusive disease.
*P-value represents the comparison of each characteristic according
to the KIR-ligand group.
aAmong non-relapse-related deaths.
bFisher’s exact test.
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in only a minority of donors as most possess a full complement
of inhibitory KIR genes and have the potential to exert NK
alloreactions. Moreover, the risk of misclassification arises when
the donor does not possess/express the relevant KIR to exert
alloreactivity. Under this circumstance, KIR-ligand mismatching
mistakenly classifies a non-NK-alloreactive transplant pair as NK
alloreactive. Therefore, in our series, such ‘false positives’ might
have ‘contaminated/diluted’ the NK-alloreactive cohort. Thus,
the only conceivable consequence of such misclassification is
an underestimation of the effects of NK alloreactivity, which
reinforces, rather than detracts from, our core observation that
NK-cell alloreactivity favorably impacts on outcomes of cord
blood transplantation.
Our findings in UCBT are in agreement with those of the
Perugia group, which, using haploidentical family donor SCT, has
shown that KIR-ligand incompatibility in the GvH direction is
associated with a decreased incidence of graft failure, GvHD and
relapse, and an improved survival of patients with AML.7–9 They
explain their clinical results by findings from mouse experiments
and human in vitro data in which donor-versus-recipient
alloreactive NK cells eliminate residual leukemic cells, ablate
host-type dendritic cells responsible for triggering GvHD and
attack residual host lymphohematopoietic cells, including T
cells, that are responsible for graft rejection.8 Our present
analyses show that KIR-ligand incompatibility has a stronger
effect on RI, LFS and OS in AML patients than in ALL patients.
This finding is in accordance with clinical and in vitro data from
Ruggeri et al.,8 who showed that AML cells were killed in vitro
by alloreactive NK clones, whereas only a sub-population of
ALL cells was sensitive to NK-cell alloreactivity. As we observed
a small but consistent KIR-ligand effect in our ALL patients, the
data suggest that subgroups of ALL (T- or B-lineage ALL) may
show differential sensitivities to donor NK-cell alloreactivity.
This study provides for the first time information on the role of
HLA-A3/-A11 KIR-ligand mismatches in transplantation, which
had been lacking until now, as they were not reported in
haploidentical transplants. Surprisingly, HLA-A3/-A11 mis-
matching in the GvH direction emerged as just as good a
predictor of favorable prognosis as HLA-C and HLA-Bw4 group
mismatches. Our use of HLA-A3/-A11 mismatching as a
predictor of NK-cell alloreactivity may be criticized, as the role
of HLA-A3/-A11 as a ligand for KIR3DL2 is controversial. As
HLA-A3/-A11 alleles were reported to function as KIR ligands
when bound to EBV peptides,6 it seems reasonable that, in view
of frequent EBV reactivation after transplantation, EBV peptides
were readily available for HLA-A3/-A11 binding, with the
possible generation of HLA-A3/-A11-specific donor NK cells
that were alloreactive against target cells from recipients lacking
HLA-A3 and/or HLA-A11. In our data set, EBV status was
reported in only 74 patients (36%), of which 58 (78%) were EBV
positive. No data on EBV reactivation are available in the
Eurocord database. Thus, the role of HLA-A3/-A11 as a KIR
ligand cannot be further supported in this study.
This analysis shows that donor-versus-recipient NK-cell
alloreactivity exerts a beneficial impact not only in haploiden-
tical but also in cord blood transplantation. These two types of
SCT have in common that the donors are highly HLA
mismatched with the recipient, whereas after SCT, relatively
little severe GvHD is observed. The post-transplant period is
further characterized by a rapid recovery of NK cells and long-
lasting T-cell immunoincompetence. As T cells in the cord
blood graft are antigen inexperienced, they contain few or no
cytotoxic T cells directed against viral and bacterial peptides,
which may cross-react with HLA alloantigens. The relative lack
of post-thymic T cells and the T-cell naivety may be responsible
for the lower-than expected frequency of severe GvHD, even in
the setting of one or two HLA mismatches, and for the delayed
recovery of T-cell function after UCBT31–33 to the same degree
as after haploidentical SCT. Lack of memory T cells in the graft
(due to T-cell depletion in haploidentical and T-cell naivety in
cord blood transplants) apparently permits the recovery of fully
functional NK cells. Interestingly, one study comparing T cell-
depleted-versus-repleted unrelated donor transplants demon-
strated that T cells in the graft adversely affected reconstitution
of KIR-bearing NK cells and clinical outcomes.34 Additional
evidence that T cells antagonize reconstitution of
potentially alloreactive, KIR-bearing NK cells derives from
several other unrelated donor transplant studies, using T-cell-
replete grafts.10,11,13–15,33,35 Most studies showed no advantage in
transplantation from KIR-ligand-mismatched donors,13–15,30,31,36–38
whereas a few observed an increased graft-versus-leukemia
effect.10,11,39–41
In haploidentical29,30, matched sibling12 and unrelated donor
transplants,36 the ‘missing ligand’ model was proposed as
a powerful algorithm for predicting favorable transplant
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Figure 2 (a) Estimated leukemia-free survival in AML patients in CR
with Kir-ligand-compatible (_______) (n¼68) or -incompatible (- - - - - - -)
donors (n¼ 26), after UCBT. (b) Estimated leukemia-free survival in
ALL patients in CR with Kir-ligand-compatible (_______) (n¼81) or
-incompatible (- - - - - - -) donors (n¼ 43), after UCBT. AML, acute
myeloid leukemia; CR, complete remission; UCBT, unrelated cord
blood transplant.
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KIR-ligand-matched donors possess KIR(s) for which neither
donor nor recipient has an HLA ligand(s). These donors were
shown to carry KIR-bearing NK cells in an anergic/regulated
state.42 The ‘missing ligand’ model proposes that, upon transfer
into the recipient, they may become activated and exert a graft-
versus-leukemia effect. However, in the UCBT setting, as in a
recent haploidentical transplant study,9 no informative results
emerged when we analyzed the outcomes of ‘missing ligand’
transplants (data not shown).
In conclusion, in patients with acute leukemia in CR, single-
unit UCBT from donors who are KIR-ligand mismatched (for
HLA-C group, HLA-Bw4 group and/or HLA-A3/-A11) in the
GvH direction resulted in a lower incidence of relapse and in an
improved LFS and OS as compared with UCBT from KIR-ligand-
compatible donors. If these results are confirmed in a larger
series of patients, KIR-ligand incompatibility in the GvH
direction might be considered as a criterion for cord blood
donor choice.
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